MDHHS – MCIR Release Notes

Version 2022 – MCIR OLTP 2022 9.3.0.9.6.6 – RFC 211224 Release Date: December 21, 2022

Forecast & Assessment

The following CVX Codes have been updated to support non-US vaccines. There are all historical under Other.

- CVX 518 COVID-19 Non-US vaccines (Ref. #1943)
- CVX 519 COVID-19 Non-US vaccines (Ref. #1969)
- CVX 520 COVID-19 Non-US vaccines (Ref. #1970)

The MCIR.org code set has been updated.

Forecast and evaluate Moderna COVID-19 Bivalent Boosters CVX 230 Moderna Bivalent Booster 10 mcg/0.2ml (Ref. #1878)

Test case – history of one dose, forecast to complete primary series

SARS-CoV-2	09/01/2022 COVID-19 MOD 25 mcg ped 3yrs 1mo	Moderna 25MCG PED DUE NOW

Status

Moderna 25MCG PED	YES	2	09/22/2022	09/22/2022	10/27/2022

Test case – primary series completed

New recommendation for children ages 6 months–4 years who complete a Moderna primary series to receive 1 bivalent Moderna booster dose at least 2 months after completion of the primary series.

SARS-CoV-2	07/01/2022 COVID-19 MOD 25 mcg ped 6mos	11/15/2022 COVID-19 MOD 25 mcg ped 10mos 14dys	Up-To-Date Next Due 01/15/2023

Status

Moderna Bivalent 10MCG PED	3	01/15/2023	01/15/2023	01/15/2023

Test case - primary series and bivalent booster administered

SARS-CoV-2	05/01/2022 COVID-19 MOD 25 mcg ped 11mos	06/01/2022 COVID-19 MOD 25 mcg ped 1yr exactly	12/08/2022 COVID-19 MOD Bivalent Booster 10mcg/0.2mL 1yr 6mos	Up-To-Date

COVID-19 (Moderna) Up-to-date

Text case- mixed primary series

Children ages 6 months–4 years who received 1 monovalent Moderna vaccine and 1 monovalent Pfizer-BioNTech vaccine for the first 2 doses of a primary series should follow a 3-dose schedule. A third dose of either a monovalent Moderna vaccine or a bivalent Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose to complete the 3-dose primary series. Currently, children in this age group who receive a mixed 3-dose primary series with any combination of Moderna and Pfizer- BioNTech vaccines cannot receive any booster dose.

COVID-19 MOD 25 mcg ped	1	3 Years 4 Months	08/01/2022
COVID-19 PFR-BNT 3mcg/0.2mL	2	3 Years 5 Months	09/01/2022
COVID-19 PFR Bivalent Booster 3mcg/0.2mL	3	3 Years 8 Months	12/09/2022

SARS-CoV-2	08/01/2022 COVID-19 MOD 25 mcg ped 3yrs 4mos	09/01/2022 COVID-19 PFR- BNT 3mcg/0.2mL 3yrs 5mos	12/09/2022 COVID-19 PFR Bivalent Booster 3mcg/0.2mL 3yrs 8mos		Up-To-Date

Forecast and evaluate Pfizer COVID-19 Bivalent as dose 3 Primary series-CVX 302 (Ref. #1879)

The previously authorized 3-dose Pfizer-BioNTech primary series for children ages 6 months–4 years has been revised as follows: a monovalent Pfizer-BioNTech vaccine is administered for the first and second doses, followed by 1 bivalent Pfizer-BioNTech vaccine as the third primary series dose, at least 8 weeks after the second monovalent primary series dose. A booster dose is not authorized for children in this age group who receive a Pfizer-BioNTech 3-dose primary series, including children who previously received a 3-dose monovalent Pfizer-BioNTech primary series.

Test case - completing 3 primary doses of monovalent before new recommendation – up to date, not eligible for bivalent dose

SARS-CoV-2	06/01/2022 COVID-19 PFR- BNT 3mcg/0.2mL 2yrs 5mos	07/01/2022 COVID-19 PFR- BNT 3mcg/0.2mL 2yrs 6mos	09/01/2022 COVID-19 PFR- BNT 3mcg/0.2mL 2yrs 8mos		Up-To-Date

Pfizer Bivalent 3MCG PED	Up-to-date

Test case - history of 2 doses, forecast for bivalent dose for dose 3 of primary series 8 weeks after dose 2

SARS-CoV-2	10/01/2022 COVID-19 PFR- BNT 3mcg/0.2mL 4yrs 2mos	11/01/2022 COVID-19 PFR- BNT 3mcg/0.2mL 4yrs 3mos			Up-To-Date Next Due 12/27/2022

Pfizer Bivalent 3MCG PED	3	12/27/2022	12/27/2022	12/27/2022

Test case- history of 2 doses monovalent, dose 3 as bivalent

SARS-CoV-2	05/01/2022 COVID-19 PFR-BNT 3mcg/0.2mL 2yrs 4mos	06/01/2022 COVID-19 PFR-BNT 3mcg/0.2mL 2yrs 5mos	12/09/2022 COVID-19 PFR Bivalent Booster 3mcg/0.2mL 2yrs 11mos	Up-To-Date

Pfizer Bivalent 3MCG PED	Up-to-date

Test case- monovalent dose given instead of bivalent dose after 12/09/22- vaccine error, do not repeat dose

SARS-CoV-2	08/01/2022 COVID-19 PFR-BNT 3mcg/0.2mL 2yrs 6mos	09/01/2022 COVID-19 PFR-BNT 3mcg/0.2mL 2yrs 7mos	12/15/2022 COVID-19 PFR-BNT 3mcg/0.2mL 2yrs 10mos	Up-To-Date

Enhancement

A weekly process has been created to auto-merge a portion of outstanding person duplicates. This will reduce the number of duplicates manually resolved by the MCIR Regional staff. (Ref. #1377)

Bug Fixes

Within the Perinatal Hepatitis B Program module, an issue has been resolved to retain the Initial Source "Other" Note Field when Adding or Editing an Event when saved. (Ref. #60)

When an LWB count exists in a Lot # when an inventory period is closed out (balanced), that count properly carries over to the new balance period. (Ref. #1585)

An issue has been corrected with COVID vaccine edit, delete, or re-entry of vaccines administered by a site. Previously a “Persistence” failure error was presented. (Ref. #1746)

An error has been corrected when attempting to view Outbreak Inventory History. Previously an exception error was presented. (Ref. #1942)

If you have questions or need assistance, please contact your Field Representative, MCIR Region, or MCIR SOM Help Desk at **MDHHS-MCIRHelp@michigan.gov**.